Lee Pitcher

To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or

To ask the Secretary of State for Health and Social Care, what information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms a

To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each li

To ask the Secretary of State for Health and Social Care, what data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse c

To ask the Secretary of State for Health and Social Care, what assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairmen

To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing n

To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs synd

To ask the Secretary of State for Health and Social Care, what information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder d

To ask the Secretary of State for Health and Social Care, how many Yellow Card reports have (a) listed pramipexole, ropinirole, rotigotine and cabergoline as a suspected medicine and (b) included any

To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients exposed to dopamine agonists for (a) Parkinson’s disease and (b) restless legs